Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · IEX Real-Time Price · USD

1.870

-0.110 (-5.56%)

At close: Apr 19, 2024, 4:00 PM

1.890

+0.020 (1.07%)

After-hours: Apr 19, 2024, 4:15 PM EDT

Amylyx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	380.79	22.23	0.29	0.65	1.43
Revenue Growth (YoY)	1612.94%	7700.00%	-56.15%	-54.42%	-
Cost of Revenue	25.44	2.99	0	0	0
Gross Profit	355.35	19.24	0.29	0.65	1.43
Selling, General & Admin	188.36	127.13	38.93	15.06	3.08
Research & Development	128.19	93.45	44.04	24.59	11.9
Operating Expenses	316.54	220.58	82.97	39.66	14.98
Operating Income	38.8	-201.34	-82.69	-39.01	-13.55
Interest Expense / Income	0	0	0	2.29	1.28
Other Expense / Income	-15.5	-3.74	5.24	0.99	-1.11
Pretax Income	54.3	-197.6	-87.93	-42.28	-13.72
Income Tax	5.03	0.77	0	0	0
Net Income	49.27	-198.38	-87.93	-42.28	-13.72
Shares Outstanding (Basic)	67	58	7	6	6
Shares Outstanding (Diluted)	70	58	7	6	6
Shares Change	19.65%	788.13%	8.37%	3.20%	-
EPS (Basic)	0.73	-3.39	-13.35	-6.96	-2.33
EPS (Diluted)	0.70	-3.39	-13.35	-6.96	-2.33
Free Cash Flow	10.68	-182.4	-75.15	-36.85	-10.69
Free Cash Flow Per Share	0.16	-3.12	-11.41	-6.06	-1.81
Gross Margin	93.32%	86.54%	100.00%	100.00%	100.00%
Operating Margin	10.19%	-905.72%	-29013.33%	-6000.77%	-950.49%
Profit Margin	12.94%	-892.38%	-30852.98%	-6504.62%	-961.85%
Free Cash Flow Margin	2.80%	-820.50%	-26369.12%	-5668.92%	-749.44%
Effective Tax Rate	9.26%	-	-	-	-
EBITDA	55.39	-197.11	-87.88	-39.99	-12.44
EBITDA Margin	14.54%	-886.70%	-30834.74%	-6152.46%	-872.37%
Depreciation & Amortization	1.09	0.49	0.05	0	0
EBIT	54.3	-197.6	-87.93	-39.99	-12.44
EBIT Margin	14.26%	-888.89%	-30852.98%	-6152.62%	-872.37%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).